GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio, Inc. Common Stock

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

National Science Foundation

GRI Bio, Inc.

Our CEO, Dr. Marc Hertz, highlights our novel approach to #immunemodulation. Watch the full video here: https://bit.ly/3FvbDJn  

#NKT #AutoimmuneDisease #InflammatoryDisease #FibroticDisease

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/3GvZu7M 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

Access our library of scientific publications for a comprehensive review of our data. https://bit.ly/3OhuOf8  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

#WhatThisMeans: Drs. Marc Hertz and Al Agro, CEO and CMO of GRI Bio, Inc., highlight the Company’s recent IND clearance for lead program targeting #idiopathicpulmonaryfibrosis. 

https://lnkd.in/eUEkB7DC
#IPF #NKT #FibroticDisease

GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant #NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/47we2Qm 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

We hope your Thanksgiving table is full of your favorite food and surrounded by your favorite people.

Regulating #NKT cells is a selective approach to #immunomodulation via resetting the immune response. Learn more here: https://bit.ly/3pRUJAu  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

GRI Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update.

https://bit.ly/47ce5kt 
#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

Email alerts make it easy to stay up to date! Sign up here: https://bit.ly/45GwuVq  

#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

We are dedicated to advancing new therapies through innovative approaches for the treatment of #inflammatory, #fibrotic and #autoimmune diseases. 

#NKT

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	246.33K -	1.23M 397.71%	57K 95.35%	1.29M 2,170.18%	1.41M 8.96%
accumulated other comprehensive income loss
cash and cash equivalents	3.82M -	109K 97.15%	90K 17.43%	9K 90%	1.81M 19,988.89%
cash and short term investments	3.82M -	109K 97.15%	90K 17.43%	9K 90%	1.81M 19,988.89%
common stock	18.02K -		352K -	267K 24.15%
deferred revenue		81K -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		14K -	67K 378.57%	14K 79.10%
long term investments
net debt	-3.48M -	227K 106.52%	3.52M 1,452.42%	664K 81.16%	-1.79M 370.18%
net receivables
other assets	1 -	1 0%			1 -
other current assets	100.86K -	565K 460.18%	6K 98.94%	299K 4,883.33%	1.13M 276.59%
other current liabilities	475.50K -	766K 61.09%	1.27M 65.93%	41K 96.77%	1.27M 3,004.88%
other liabilities		1 -
other non current assets	-1 -	-1 0%	5K 500,100%	4K 20%	-1 100.03%
other non current liabilities		170.00K -
othertotal stockholders equity	10.97M -	11.14M 1.57%	10.20M 8.45%	16.60M 62.74%	31.79M 91.47%
preferred stock
property plant equipment net	353.90K -	281K 20.60%	117K 58.36%	71K 39.32%	22K 69.01%
retained earnings	-7.78M -	-12.60M 62.00%	-15.28M 21.27%	-18.50M 21.06%	-31.53M 70.49%
short term debt	85.67K -	152K 77.44%	3.55M 2,233.55%	659K 81.42%	14K 97.88%
short term investments
tax assets
tax payables
total assets	4.28M -	955K 77.66%	218K 77.17%	383K 75.69%	2.96M 671.80%
total current assets	3.92M -	674K 82.81%	96K 85.76%	308K 220.83%	2.93M 852.60%
total current liabilities	807.50K -	2.23M 175.54%	4.88M 119.10%	1.99M 59.10%	2.70M 35.26%
total debt	340.02K -	336K 1.18%	3.61M 975.60%	673K 81.38%	14K 97.92%
total investments
total liabilities	1.06M -	2.41M 126.87%	4.94M 105.15%	2.01M 59.37%	2.70M 34.31%
total liabilities and stockholders equity	4.28M -	955K 77.66%	218K 77.17%	383K 75.69%	2.96M 671.80%
total non current assets	353.90K -	281.00K 20.60%	122K 56.58%	75K 38.52%	22.00K 70.67%
total non current liabilities	254.36K -	184.00K 27.66%	67K 63.59%	14K 79.10%
total stockholders equity	3.21M -	-1.45M 145.24%	-4.72M 224.90%	-1.63M 65.60%	259K 115.94%

COM:GRIBIO

GRI Bio, Inc.

Last Close

1.27

26/07 20:00

Market Cap

1.59M

Beta: -

Volume Today

457.28K

Avg: -

Preview